期刊
DRUG DISCOVERY TODAY
卷 15, 期 19-20, 页码 816-825出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.07.006
关键词
-
资金
- Cancer Research UK
- Experimental Cancer Medicine Centre
The introduction of new anticancer drugs into the clinic is often hampered by a lack of qualified biomarkers. Method validation is indispensable to successful biomarker qualification and is also a regulatory requirement. Recently, the fit-for-purpose approach has been developed to promote flexible yet rigorous biomarker method validation, although its full implications are often overlooked. This review aims to clarify many of the scientific and regulatory issues surrounding biomarker method validation and the analysis of samples collected from clinical trial subjects. It also strives to provide clear guidance on validation strategies for each of the five categories that define the majority of biomarker assays, citing specific examples.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据